STOCK TITAN

Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Sight Sciences, Inc. (Nasdaq: SGHT) will report its financial results for the fourth quarter and full year ending December 31, 2022, on March 13, 2023, after market close. The management will discuss the results in a conference call at 1:30 PM PT / 4:30 PM ET. Investors can listen live or access a replay on the company's website for at least 90 days. Sight Sciences focuses on innovative eye care solutions, including the OMNI® Surgical System for glaucoma and the TearCare® System for dry eye disease. These products aim to improve patient outcomes through minimally invasive techniques, addressing significant health issues in eye care.

Positive
  • Innovative product portfolio targeting prevalent eye diseases.
  • OMNI® Surgical System and TearCare® System are minimally invasive, improving patient care.
Negative
  • None.

MENLO PARK, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2022, after the market close on Monday, March 13, 2023. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.com, on the Investors page in the News & Events section. The webcast will be available for replay for at least 90 days after the event.

About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company’s SION™ Surgical Instrument is a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.

For more information, visit www.sightsciences.com.

OMNI® and TearCare® are registered trademarks of Sight Sciences.
SION™ is a trademark of Sight Sciences.
© 2023 Sight Sciences. All rights reserved.

Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com


FAQ

When will Sight Sciences report its Q4 and full year results for 2022?

Sight Sciences will report its financial results on March 13, 2023.

What products does Sight Sciences focus on?

Sight Sciences focuses on the OMNI® Surgical System for glaucoma and the TearCare® System for dry eye disease.

How can I access the earnings call for Sight Sciences?

Investors can access the conference call via a live and archived webcast on the company’s website.

What time is the conference call for Sight Sciences' financial results?

The conference call will begin at 1:30 PM PT / 4:30 PM ET.

Sight Sciences, Inc.

NASDAQ:SGHT

SGHT Rankings

SGHT Latest News

SGHT Stock Data

230.41M
50.31M
20.08%
50.9%
2.22%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
MENLO PARK